MARKET

ARTL

ARTL

Artelo Biosciences Inc
NASDAQ
1.220
+0.060
+5.17%
After Hours: 1.190 -0.03 -2.46% 19:26 12/31 EST
OPEN
1.150
PREV CLOSE
1.160
HIGH
1.220
LOW
1.150
VOLUME
51.22K
TURNOVER
--
52 WEEK HIGH
28.60
52 WEEK LOW
1.150
MARKET CAP
2.46M
P/E (TTM)
-0.0584
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARTL last week (1222-1226)?
Weekly Report · 12/29/2025 09:42
Artelo Biosciences Plans Clinical Development Of ART12.11 CBD Therapy Following White House Medicare Pilot Executive Order
Benzinga · 12/23/2025 14:05
Artelo comments on White House Executive Order expanding CBD research
TipRanks · 12/23/2025 14:05
Weekly Report: what happened at ARTL last week (1215-1219)?
Weekly Report · 12/22/2025 09:42
Weekly Report: what happened at ARTL last week (1208-1212)?
Weekly Report · 12/15/2025 09:46
Artelo Biosciences Inc. Announces Date for 2025 Annual Meeting of Stockholders
Reuters · 12/11/2025 21:06
Weekly Report: what happened at ARTL last week (1201-1205)?
Weekly Report · 12/08/2025 09:46
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 12/03/2025 21:06
More
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Webull offers Artelo Biosciences Inc stock information, including NASDAQ: ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.